Dr. Narjust Florez, who helped bring the session to fruition, will join other successful women in lung cancer as well as Her Royal Highness Princess Dina Mired of Jordan to discuss experiences, concerns, and solutions.
Compared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European…
Dr. Jeffrey D. Bradley presented the data from the phase III study of durvalumab in combination with and following chemoradiotherapy for patients with unresectable, stage…
Drs. Christi M.J. Steendam and Sushil K. Badrising review studies comparing outcomes of various treatment regimens in the search for the best-performing approach.
Ask your lawmakers to sign “Dear Colleague” letters urging increased funding for the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
The association seeks input from members to better understand the current DEI landscape so it can continue to build a diverse international community dedicated to…
The filing was based on results from a global phase III study designed to compare the ALK inhibitor to crizotinib in the first-line treatment of…
Profs. Jan von der Thüsen and John Le Quesne say while still in the early phases, AI has the potential to bring accessible and affordable…
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact.
Nathan Pennell: First published article in the 2024 ASCO Educational Book / ASCO, cancer, Cleveland Clinic Taussig Cancer Institute, Mariam Mailyan, Nathan
